Bluebird Bio Faces Nasdaq Compliance Challenge and Delays
Express News | Bluebird bio Announces Receipt of Expected Notice From Nasdaq
Cerebral Adrenoleukodystrophy Pipeline Insight 2024, Featuring Key Players Minoryx Therapeutics, POXEL, Orpheris and Bluebird Bio
Express News | Bluebird Bio Inc Anticipates It Will Be Delayed In Filing Its Quarterly Report On Form 10-Q For Q1 Of 2024
Express News | bluebird bio Shares Down 9% at $0.90 After the Bell Following Announcement of Delay in 10-Q Filing
Express News | bluebird bio Inc - Anticipates It Will Be Delayed in Filing Its Quarterly Report on Form 10-Q for the First Quarter of 2024
TD Cowen Says Sickle Cell Therapies May Get Higher CMS Payments
Express News | Watching Bluebird Bio; Shares Spike Higher As Traders Circulating Unconfirmed Rumor Suggesting "Lyfgenia Is Among 8 New Therapies In The Running To Receive NTAP Designations At The Start Of FY25. The Emphasis On Supporting Access For SCD Therapies Across
Is Bluebird Bio Stock a Buy?
Better Buy: Bluebird Bio Vs. Novavax
Is This Beaten-Down Stock a Good Acquisition Target?
Bluebird Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ)
Bluebird Bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Call Transcript
Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Bluebird Bio (BLUE)
Peeling Back The Layers: Exploring Bluebird Bio Through Analyst Insights
During the last three months, 4 analysts shared their evaluations of bluebird bio (NASDAQ:BLUE), revealing diverse outlooks from bullish to bearish.The following table encapsulates their recent rating
RBC Capital Reiterates Sector Perform on Bluebird Bio, Maintains $6 Price Target
RBC Capital analyst Luca Issi reiterates bluebird bio with a Sector Perform and maintains $6 price target.
Bluebird Biotech Set to Outperform Pessimistic Expectations – Broker | NASDAQ:BLUE
Bluebird Bio Is Maintained at Equal-Weight by Wells Fargo
Bluebird Bio Is Maintained at Equal-Weight by Wells Fargo
No Data